Genzyme To Expand Presence In Oncology Through Licensing Deals In 2004
Genzyme is looking to expand its presence in oncology through in-licensing activities in 2004
You may also be interested in...
The merger of Genzyme and Novazyme does not merit antitrust activity because it does not result in the delay of Pompe therapy development, the Federal Trade Commission said Jan. 13
Schering-Plough is focusing its in-licensing activities on specialty biotechnology products, CEO Fred Hassan told analysts during the company's business review in New York City Nov. 18
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011